OSE Immunotherapeutics

89 articles with OSE Immunotherapeutics

• 

  Clinical Catch-Up: July 19-23

  7/26/2021

  It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.

• OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

  7/19/2021

  OSE Immunotherapeutics SA   today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial for CoVepiT, the company’s investigational prophylactic COVID-19 vaccine candidate.

• OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank

  7/9/2021

  OSE Immunotherapeutics announced a €10 million payment corresponding to the first tranche of the financing granted by the European Investment Bank.

• OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine

  6/30/2021

  OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization, announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate against COVID-19 currently in Phase 1 clinical trial, which will be used in the product’s development phases.

• OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting

  6/24/2021

  OSE Immunotherapeutics announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.

• OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer

  5/27/2021

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and the FoRT Foundation (Fondazione Ricerca Traslazionale) today announced that the Italian Medicines Agency (AIFA) and the Italian Ethics Committee approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in combination with Opdivo® or chemotherapy as second-line treatment in patients with metastatic non-small cell lung cancer (NSCLC).

• OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

  5/26/2021

  OSE Immunotherapeutics announced that the first healthy volunteer has been enrolled and dosed in the Phase 1 clinical trial evaluating its COVID-19 vaccine, named CoVepiT.

• OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021

  5/20/2021

  BI 765063, a first-in-class SIRPα inhibitor on the SIRPα/CD47 “Don’t eat me” pathway, is undercollaborative development with Boehringer Ingelheim.

• OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase

  5/18/2021

  CoVepiT epitopes* are selected from 11 viral protein targets designed to cover all initial and new emerging SARS-CoV-2 variants.

• 

  Preparing a Pandemic Plan for Whatever Comes Our Way Next

  4/28/2021

  According to Teo, the definition of the next pandemic depends a lot on one’s perspective.

• OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104

  4/26/2021

  Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients. OSE Immunotherapeutics to receive up to €315 million in potential milestones,  including a €7 million upfront, and tiered royalties on sales.

• OSE Immunotherapeutics Announces First Peer-Reviewed Publication in "Science Advances" on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation

  4/6/2021

  OSE Immunotherapeutics announced the first peer-reviewed publication on OSE-230, a novel and innovative approach in the management of the resolution of chronic and severe inflammation, in Science Advances.

• OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

  4/1/2021

  CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope* responses. CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and new emerging SARS-CoV-2 variants.

• OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update

  3/26/2021

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2020 and provided an update on key achievements, as well as the Company’s outlook for 2021 for its immunotherapies in T-cell vaccines, immuno-oncolog

• OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

  3/15/2021

  OSE Immunotherapeutics and the French cooperative group ARCAGY-GINECO announced that the French National Agency for Medicines and Health Products Safety and the French Central Ethic Committee approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in patients with recurrent ovarian cancer.

• OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting

  3/11/2021

  CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation. BiCKI ® -IL-7, bifunctional therapy targeting PD-1 and IL-7 to sustain exhausted T cell function and to disarm Treg suppressive activity.

• OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference

  2/23/2021

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of the Company’s business at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-11, 2021.

• OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011Covers therapeutic applications of OSE-127/S95011 through 2037

  2/17/2021

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that it has strengthened intellectual property rights for its anti-interleukin-7 receptor (IL-7R) antagonist OSE-127/S95011 through the granting of a first patent by the European Patent Office (EPO). The patent covers the product and its therapeutic applications in autoimmune and inflammatory diseases through 2037.

• OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

  2/15/2021

  This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high unmet medical needs,

• OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

  1/28/2021

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced a new collaboration agreement with MAbSilico, a deep technology innovative TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.